Cell3™ Target: Whole Exome Enrichment

Whole exome sequencing

Optimised whole exome coverage delivering higher sample throughput and reducing sequencing costs.

Focused exonic content

Our optimized exome covers 33Mb of highly-conserved protein coding regions and 99% of ClinVar variants, so you can focus on what matters.

Optimized performance

Delivering excellent uniformity of coverage, Cell3™ Target Whole Exome minimises low coverage regions reducing sequencing costs and improving sample throughput

 

Range of sample types

Cell3™ Target Whole Exome supports a broad range of sample types, including cell free, genomic and formalin-fixed, paraffin-embedded (FFPE) DNA.

Customisable

Designed to be flexible, Cell3™ Target Whole Exome allows you to add extra content to cover targets specific to your project.

Whole Exome enrichment

Whole exome sequencing has been widely adopted in the last decade as an efficient way of screening the genome for disease-associated mutations. By focusing reads on coding regions, which contain more than 80% of known disease-causing variants, the probability of identifying mutations associated with disease is increased. At the same time, the amount of exome sequencing (and analysis) required is reduced by 99% when compared to whole genomes, significantly reducing the cost of sequencing. This makes whole exome sequencing an efficient and cost-effective alternative to whole-genome sequencing especially in clinical applications.

Exome content focused on what matters

The Cell3™ Target Whole Exome focuses on the core protein-coding regions referenced in CCDS. Using a 33Mb design (37Mb sequencing footprint) covering 99% of ClinVar variants, we achieve coverage of >97% of targeted regions at >= 20x coverage with a 150x mean sequencing depth and requiring just 4.90Gb of sequencing per sample.

By focusing on what matters, the Cell3™ Target Whole Exome offers you a cost effective and efficient whole exome solution and the choice of running more samples or samples at greater depth, than other exome products.

whole exome enrichment
Exome capture uniformity of coverage

Optimised exome sequencing performance

The baits used in Cell3™ Target Whole Exome are designed to deliver excellent uniformity of coverage. By improving uniformity of coverage and reducing the number of low-coverage exons, our whole exome enrichment optimises sequencing efficiency and sample capacity per sequencing run.

Broad range of sample types including FFPE

We know that you may want to use the same exome product on multiple sample types – especially for testing matched samples. The Cell3™ Target Whole Exome sequencing kit has been developed for and validated on a broad range of sample types, including cell-free (circulating tumor (ctDNA) and cell-free fetal (cff DNA)), genomic, and both fresh frozen and formalin-fixed, paraffin-embedded (FFPE) DNA.

Using from as little as 1 ng of genomic or cfDNA (10 ng of FFPE), Cell3™ Target Whole Exome unlocks the door for prenatal and oncology applications

Diagram demonstrating Using UMI’s to identify and quantify individual DNA molecules during library preparation increases sensitivity

Figure 1. Using UMI’s to identify and quantify individual DNA molecules during library preparation increases sensitivity

Detect low frequency mutations for prenatal or cancer research

The Cell3™ Target library preparation behind our whole exome enrichment incorporates error suppression technology. This includes unique molecular indexes (UMIs) and unique dual indexes (UDIs), to remove both PCR and sequencing errors and index hopping events. This error suppression technique, combined with our excellent uniformity of coverage, allows you to confidently and accurately call mutations down to 0.1% VAF and enables generation of exome sequencing libraries from as little as 1 ng cfDNA input.

 

Customisable content on whole exome products

Designed to be flexible, our Cell3™ Target Whole Exome allows you to add extra content specific to your project. Whether this is additional content or increased coverage of existing content, our Panel Design Tool makes this a simple and easy process to implement. And our rapid production turnaround means you will receive a fully NGS-validated custom exome within 4 weeks.

  • Additional content with high enrichment uniformity
  • Increased coverage of specific genes covered by Cell3™ Target Whole Exome
  • Optimization of spike-in ratio

Log into the Panel Design Tool at MyNonacus  to start the design process and get a quote or request further information at info@nonacus.com

Ordering Information

Cell3 Target panels are available with one of two versions of our library preparation kits:

-Fragmentation: for use with gDNA (FF or FFPE)

-Non-Fragmentation: for use with cell free DNA

Cell3™ Target: Whole Exome, Frag 16 samples NGS_C3T_WEX_FR_16
Cell3™ Target, Whole Exome, Frag 96 samples NGS_C3T_WEX_FR_96_A/B/C/D*
Cell3™ Target, Whole Exome, Non Frag 16 samples NGS_C3T_WEX_NF_16
Cell3™ Target, Whole Exome, Non Frag 96 samples NGS_C3T_WEX_NF_96_A/B/C/D*

* To provide flexibility in multiplexing samples, our 96-sample kits offer a choice in adapter plate:

A = Adapter plate with indexes 1-96
B = Adapter plate with indexes 97-192
C = Adapter plate with indexes 193-288
D = Adapter plate with indexes 289-384

Whole Exome Sequencing Product Resources


                                                                       

 

For Research Use Only. Not for use in diagnostic procedures.

 

Product Support

If you have a query relating to any of our products, including the Fetal RhD Genotyping kits, Nexome, Custom NGS Panels, or Whole Exome Enrichment, please take a look at our FAQs or complete our Contact me form and one of our team will get back to you as soon as possible.

Learn more about our other exome products

Exome enrichment for cytogenetics

ExomeCG

Clinically enhanced exome capture for whole exome sequencing and copy number analysis in a single test

DNA sequencing for cancer diagnostics

Tumor Exome

Exome capture designed for cancer research covering key intronic regions like promoters and genome-wide coverage of CNVs